Pune-based Gennova Biopharmaceuticals has submitted the phase-II and phase-III trials data of India's first mRNA Covid vaccine to the regulator Drugs Controller General of India (DCGI) on Friday, said sources. The company has also developed an Omicron-specific vaccine which will be tested on humans for efficacy and immunogenicity.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ADqHUVa
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Phase 2,3 trial data of India's first mRNA COVID vaccine submitted to DCGI
https://ift.tt/7KYiAqD
No comments:
Post a Comment